Aberrant methylation of Reprimo in human malignancies

Takao Takahashi, Makoto Suzuki, Hisayuki Shigematsu, Narayan Shivapurkar, Chinyere Echebiri, Masaharu Nomura, Victor Stastny, Meena Augustus, Chew Wun Wu, Ignacio I. Wistuba, Stephen Meltzer, Adi F. Gazdar

Research output: Contribution to journalArticle

Abstract

Reprimo is a new candidate mediator of p53-mediated cell cycle arrest at the G2 phase. Loss of Reprimo gene expression accompanied by its promoter methylation was identified in pancreatic and lung cancers. Our aim was to examine the methylation status of Reprimo in a broad range of cancers. We examined Reprimo expression by RT-PCR and the DNA methylation status of the Reprimo promoter by MSP in 39 tumor cell lines. Loss or down-regulation of Reprimo expression was frequent (62%), and we confirmed that transcriptional repression of Reprimo was caused by hypermethylation (overall concordance 92%). Treatment of expression-negative cells with 5-aza-2′-deoxycytidine restored Reprimo expression. We then examined aberrant methylation of Reprimo in 645 tumors representing 16 tumor types. Promoter methylation of Reprimo was found in 79% of gastric cancers, 62% of gallbladder cancers, 57% of lymphomas, 56% of colorectal cancers, 40% of esophageal adenocarcinomas, 37% of breast cancers and 31% of leukemias. Methylation frequencies in ovarian cancers, bladder cancers, cervical cancers, brain tumors, malignant mesotheliomas and pediatric tumors were lower (0-20%). Reprimo methylation was rarely detected in nonmalignant tissues (0-11%) except for gastric epithelia. While colorectal polyps were also frequently methylated (27%), chronic cholecystitis samples were infrequently methylated (4%). Furthermore, we failed to identify Reprimo mutation in colorectal and gastric cancer cell lines and 50 primary colorectal cancers. Aberrant methylation of Reprimo with loss of expression is a common event and may contribute to the pathogenesis of some types of human malignancy.

Original languageEnglish (US)
Pages (from-to)503-510
Number of pages8
JournalInternational Journal of Cancer
Volume115
Issue number4
DOIs
StatePublished - Jul 1 2005
Externally publishedYes

Fingerprint

Methylation
Neoplasms
Gallbladder Neoplasms
Colorectal Neoplasms
decitabine
Urinary Bladder Neoplasms
Brain Neoplasms
Stomach Neoplasms
Cholecystitis
G2 Phase
DNA Methylation
Polyps
Cell Cycle Checkpoints
Tumor Cell Line
Pancreatic Neoplasms
Uterine Cervical Neoplasms
Ovarian Neoplasms
Lymphoma
Lung Neoplasms
Stomach

Keywords

  • Human cancer
  • Methylation
  • Reprimo

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Takahashi, T., Suzuki, M., Shigematsu, H., Shivapurkar, N., Echebiri, C., Nomura, M., ... Gazdar, A. F. (2005). Aberrant methylation of Reprimo in human malignancies. International Journal of Cancer, 115(4), 503-510. https://doi.org/10.1002/ijc.20910

Aberrant methylation of Reprimo in human malignancies. / Takahashi, Takao; Suzuki, Makoto; Shigematsu, Hisayuki; Shivapurkar, Narayan; Echebiri, Chinyere; Nomura, Masaharu; Stastny, Victor; Augustus, Meena; Wu, Chew Wun; Wistuba, Ignacio I.; Meltzer, Stephen; Gazdar, Adi F.

In: International Journal of Cancer, Vol. 115, No. 4, 01.07.2005, p. 503-510.

Research output: Contribution to journalArticle

Takahashi, T, Suzuki, M, Shigematsu, H, Shivapurkar, N, Echebiri, C, Nomura, M, Stastny, V, Augustus, M, Wu, CW, Wistuba, II, Meltzer, S & Gazdar, AF 2005, 'Aberrant methylation of Reprimo in human malignancies', International Journal of Cancer, vol. 115, no. 4, pp. 503-510. https://doi.org/10.1002/ijc.20910
Takahashi T, Suzuki M, Shigematsu H, Shivapurkar N, Echebiri C, Nomura M et al. Aberrant methylation of Reprimo in human malignancies. International Journal of Cancer. 2005 Jul 1;115(4):503-510. https://doi.org/10.1002/ijc.20910
Takahashi, Takao ; Suzuki, Makoto ; Shigematsu, Hisayuki ; Shivapurkar, Narayan ; Echebiri, Chinyere ; Nomura, Masaharu ; Stastny, Victor ; Augustus, Meena ; Wu, Chew Wun ; Wistuba, Ignacio I. ; Meltzer, Stephen ; Gazdar, Adi F. / Aberrant methylation of Reprimo in human malignancies. In: International Journal of Cancer. 2005 ; Vol. 115, No. 4. pp. 503-510.
@article{959bbcf65f4f4536ba5071d513430bb5,
title = "Aberrant methylation of Reprimo in human malignancies",
abstract = "Reprimo is a new candidate mediator of p53-mediated cell cycle arrest at the G2 phase. Loss of Reprimo gene expression accompanied by its promoter methylation was identified in pancreatic and lung cancers. Our aim was to examine the methylation status of Reprimo in a broad range of cancers. We examined Reprimo expression by RT-PCR and the DNA methylation status of the Reprimo promoter by MSP in 39 tumor cell lines. Loss or down-regulation of Reprimo expression was frequent (62{\%}), and we confirmed that transcriptional repression of Reprimo was caused by hypermethylation (overall concordance 92{\%}). Treatment of expression-negative cells with 5-aza-2′-deoxycytidine restored Reprimo expression. We then examined aberrant methylation of Reprimo in 645 tumors representing 16 tumor types. Promoter methylation of Reprimo was found in 79{\%} of gastric cancers, 62{\%} of gallbladder cancers, 57{\%} of lymphomas, 56{\%} of colorectal cancers, 40{\%} of esophageal adenocarcinomas, 37{\%} of breast cancers and 31{\%} of leukemias. Methylation frequencies in ovarian cancers, bladder cancers, cervical cancers, brain tumors, malignant mesotheliomas and pediatric tumors were lower (0-20{\%}). Reprimo methylation was rarely detected in nonmalignant tissues (0-11{\%}) except for gastric epithelia. While colorectal polyps were also frequently methylated (27{\%}), chronic cholecystitis samples were infrequently methylated (4{\%}). Furthermore, we failed to identify Reprimo mutation in colorectal and gastric cancer cell lines and 50 primary colorectal cancers. Aberrant methylation of Reprimo with loss of expression is a common event and may contribute to the pathogenesis of some types of human malignancy.",
keywords = "Human cancer, Methylation, Reprimo",
author = "Takao Takahashi and Makoto Suzuki and Hisayuki Shigematsu and Narayan Shivapurkar and Chinyere Echebiri and Masaharu Nomura and Victor Stastny and Meena Augustus and Wu, {Chew Wun} and Wistuba, {Ignacio I.} and Stephen Meltzer and Gazdar, {Adi F.}",
year = "2005",
month = "7",
day = "1",
doi = "10.1002/ijc.20910",
language = "English (US)",
volume = "115",
pages = "503--510",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Aberrant methylation of Reprimo in human malignancies

AU - Takahashi, Takao

AU - Suzuki, Makoto

AU - Shigematsu, Hisayuki

AU - Shivapurkar, Narayan

AU - Echebiri, Chinyere

AU - Nomura, Masaharu

AU - Stastny, Victor

AU - Augustus, Meena

AU - Wu, Chew Wun

AU - Wistuba, Ignacio I.

AU - Meltzer, Stephen

AU - Gazdar, Adi F.

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Reprimo is a new candidate mediator of p53-mediated cell cycle arrest at the G2 phase. Loss of Reprimo gene expression accompanied by its promoter methylation was identified in pancreatic and lung cancers. Our aim was to examine the methylation status of Reprimo in a broad range of cancers. We examined Reprimo expression by RT-PCR and the DNA methylation status of the Reprimo promoter by MSP in 39 tumor cell lines. Loss or down-regulation of Reprimo expression was frequent (62%), and we confirmed that transcriptional repression of Reprimo was caused by hypermethylation (overall concordance 92%). Treatment of expression-negative cells with 5-aza-2′-deoxycytidine restored Reprimo expression. We then examined aberrant methylation of Reprimo in 645 tumors representing 16 tumor types. Promoter methylation of Reprimo was found in 79% of gastric cancers, 62% of gallbladder cancers, 57% of lymphomas, 56% of colorectal cancers, 40% of esophageal adenocarcinomas, 37% of breast cancers and 31% of leukemias. Methylation frequencies in ovarian cancers, bladder cancers, cervical cancers, brain tumors, malignant mesotheliomas and pediatric tumors were lower (0-20%). Reprimo methylation was rarely detected in nonmalignant tissues (0-11%) except for gastric epithelia. While colorectal polyps were also frequently methylated (27%), chronic cholecystitis samples were infrequently methylated (4%). Furthermore, we failed to identify Reprimo mutation in colorectal and gastric cancer cell lines and 50 primary colorectal cancers. Aberrant methylation of Reprimo with loss of expression is a common event and may contribute to the pathogenesis of some types of human malignancy.

AB - Reprimo is a new candidate mediator of p53-mediated cell cycle arrest at the G2 phase. Loss of Reprimo gene expression accompanied by its promoter methylation was identified in pancreatic and lung cancers. Our aim was to examine the methylation status of Reprimo in a broad range of cancers. We examined Reprimo expression by RT-PCR and the DNA methylation status of the Reprimo promoter by MSP in 39 tumor cell lines. Loss or down-regulation of Reprimo expression was frequent (62%), and we confirmed that transcriptional repression of Reprimo was caused by hypermethylation (overall concordance 92%). Treatment of expression-negative cells with 5-aza-2′-deoxycytidine restored Reprimo expression. We then examined aberrant methylation of Reprimo in 645 tumors representing 16 tumor types. Promoter methylation of Reprimo was found in 79% of gastric cancers, 62% of gallbladder cancers, 57% of lymphomas, 56% of colorectal cancers, 40% of esophageal adenocarcinomas, 37% of breast cancers and 31% of leukemias. Methylation frequencies in ovarian cancers, bladder cancers, cervical cancers, brain tumors, malignant mesotheliomas and pediatric tumors were lower (0-20%). Reprimo methylation was rarely detected in nonmalignant tissues (0-11%) except for gastric epithelia. While colorectal polyps were also frequently methylated (27%), chronic cholecystitis samples were infrequently methylated (4%). Furthermore, we failed to identify Reprimo mutation in colorectal and gastric cancer cell lines and 50 primary colorectal cancers. Aberrant methylation of Reprimo with loss of expression is a common event and may contribute to the pathogenesis of some types of human malignancy.

KW - Human cancer

KW - Methylation

KW - Reprimo

UR - http://www.scopus.com/inward/record.url?scp=20844443467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844443467&partnerID=8YFLogxK

U2 - 10.1002/ijc.20910

DO - 10.1002/ijc.20910

M3 - Article

C2 - 15700311

AN - SCOPUS:20844443467

VL - 115

SP - 503

EP - 510

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -